Rajat Srivastava
Fund manager Rajat Srivastava: portfolio changes across the 1 scheme AMFI's scheme summary documents name them on, Oct 2026, by share count.
Equity.
1 with AMFI average AUM, July - September 2026; each scheme in full, not split between co-managers. Source: AMFI.
On a scheme named on today, as the fund house files it. Source: AMFI SSD.
People named on at least one of the same schemes.
| Scheme | Fund house | Category | AUM | Role, as filed | Since, as filed | As of |
|---|---|---|---|---|---|---|
| Tata India Pharma & Healthcare Fund | Tata Mutual Fund | Equity Scheme - Sectoral/ Thematic | ₹1,534 cr | — | — | 3 Nov 2026 |
From each scheme's summary document on AMFI's site (scheme details), as it stood on the date shown. How to read
- ₹118 cr
- ₹84.8 cr
- ₹81.1 cr
- ₹78.7 cr
- ₹77.1 cr
- ₹70.9 cr
- ₹68.2 cr
- ₹64.1 cr
- ₹60.3 cr
- ₹48.2 cr
| Ticker | Company | Value | % of equity held | Schemes holding |
|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹118 cr | 7.9 % | 1 |
| ABBOTINDIA | Abbott India Limited | ₹84.8 cr | 5.7 % | 1 |
| DIVISLAB | Divi's Laboratories Limited | ₹81.1 cr | 5.4 % | 1 |
| HCG | Healthcare Global Enterprises Limited | ₹78.7 cr | 5.3 % | 1 |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹77.1 cr | 5.2 % | 1 |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹70.9 cr | 4.7 % | 1 |
| APOLLOHOSP | Apollo Hospitals Enterprise Limited | ₹68.2 cr | 4.6 % | 1 |
| MAXHEALTH | Max Healthcare Institute Limited | ₹64.1 cr | 4.3 % | 1 |
| RAINBOW | Rainbow Childrens Medicare Limited | ₹60.3 cr | 4.0 % | 1 |
| SAILIFE | Sai Life Sciences Limited | ₹48.2 cr | 3.2 % | 1 |
| SYNGENE | Syngene International Limited | ₹47.5 cr | 3.2 % | 1 |
| PGHL | Procter & Gamble Health Limited | ₹47.2 cr | 3.2 % | 1 |
| LUPIN | Lupin Limited | ₹46.9 cr | 3.1 % | 1 |
| CIPLA | Cipla Limited | ₹46.2 cr | 3.1 % | 1 |
| ANTHEM | Anthem Biosciences Limited | ₹44.8 cr | 3.0 % | 1 |
The 15 largest holdings by market value, summed over the schemes this manager is named on today.
1 scheme has no filed start date, so no return is shown
Each scheme's direct-growth return over the dates filed for this manager, next to its category's average. Returns and averages are computed by this site from AMFI NAVs; they are not the fund house's figures. Past performance may not be sustained in future.
| Month | Schemes with a change | Stocks added | Stocks cut | Bought | Sold | Net |
|---|---|---|---|---|---|---|
| Oct 2026 | 1 | 13 | 10 | ₹167 cr | ₹158 cr | +₹8.8 cr |
| Sep 2026 | 1 | 18 | 11 | ₹174 cr | ₹155 cr | +₹18.7 cr |
| Aug 2026 | 1 | 17 | 11 | ₹193 cr | ₹170 cr | +₹23.5 cr |
| Jul 2026 | 1 | 22 | 9 | ₹148 cr | ₹89.3 cr | +₹58.5 cr |
| Jun 2026 | 1 | 16 | 12 | ₹95.6 cr | ₹102 cr | −₹6.2 cr |
| May 2026 | 1 | 14 | 9 | ₹94.2 cr | ₹92.0 cr | +₹2.2 cr |
| Apr 2026 | 1 | 13 | 2 | ₹32.0 cr | ₹22.9 cr | +₹9.1 cr |
| Mar 2026 | 1 | 20 | 9 | ₹108 cr | ₹70.8 cr | +₹36.9 cr |
| Feb 2026 | 1 | 12 | 7 | ₹45.3 cr | ₹71.9 cr | −₹26.6 cr |
| Jan 2026 | 1 | 14 | 9 | ₹90.9 cr | ₹91.4 cr | −₹0.49 cr |
| Dec 2025 | 1 | 15 | 9 | ₹147 cr | ₹96.1 cr | +₹50.4 cr |
| Nov 2025 | 1 | 13 | 12 | ₹167 cr | ₹211 cr | −₹44.6 cr |
Across the schemes this manager is named on today, by share count.
Changes seen in AMFI's documents
since 29 Sep 2026
Changes on this manager's schemes, by the date AMFI's document first showed them.
Added 13
13 stocks · largest 13 by value
| Stock | Schemes | Implied change, share count × price | Price 30 Oct 2026, 12‑month change |
|---|---|---|---|
| BIOCON | 1 | +₹23.6 cr | ₹351.80 ▼ −5.5% |
| SANOFICONR | 1 | +₹22.0 cr | ₹3,442.30 ▼ −28.9% |
| NATCOPHARM | 1 | +₹21.3 cr | ₹782.40 ▼ −4.6% |
| NESTLEIND | 1 | +₹16.3 cr | ₹1,167.00 ▼ −8.2% |
| TORNTPHARM | 1 | +₹16.3 cr | ₹4,613.40 ▲ +29.6% |
| NAVINFLUOR | 1 | +₹13.6 cr | ₹8,680.00 ▲ +52.6% |
| MAXHEALTH | 1 | +₹12.2 cr | ₹860.00 ▼ −25.1% |
| ASTERDM | 1 | +₹10.3 cr | ₹681.15 ▲ +0.5% |
| AGARWALEYE | 1 | +₹8.7 cr | ₹509.20 ▲ +0.6% |
| SAILIFE | 1 | +₹8.0 cr | ₹1,557.50 ▲ +69.6% |
| ANTHEM | 1 | +₹7.3 cr | ₹828.80 ▲ +16.7% |
| PGHL | 1 | +₹4.9 cr | ₹5,670.50 ▼ −8.0% |
| FDC | 1 | +₹2.7 cr | ₹377.00 ▼ −18.2% |
Cut 10
10 stocks · largest 10 by value
| Stock | Schemes | Implied change, share count × price | Price 30 Oct 2026, 12‑month change |
|---|---|---|---|
| FORTIS | 1 | −₹29.5 cr | ₹768.15 ▼ −24.9% |
| PIIND | 1 | −₹28.6 cr | ₹2,100.00 ▼ −41.3% |
| LALPATHLAB | 1 | −₹25.2 cr | ₹1,906.40 ▲ +21.6% |
| CIPLA | 1 | −₹19.1 cr | ₹1,378.90 ▼ −8.2% |
| ALKEM | 1 | −₹14.3 cr | ₹5,113.50 ▼ −7.1% |
| IPCALAB | 1 | −₹13.8 cr | ₹1,927.80 ▲ +51.7% |
| MANKIND | 1 | −₹11.6 cr | ₹2,492.80 ▲ +4.6% |
| DIVISLAB | 1 | −₹9.3 cr | ₹9,780.00 ▲ +45.1% |
| SYMBIOTEC | 1 | −₹6.7 cr | ₹1,246.30 ▲ +5.9% |
| JUBLPHARMA | 1 | −₹0.01 cr | ₹923.80 ▼ −16.1% |
Each scheme's change in shares at its month-end price, summed over this manager's schemes, Oct 2026.
Questions about Rajat Srivastava
from the figures on this pageWhat stocks are in Rajat Srivastava's portfolio?
The 1 scheme Rajat Srivastava manages held 40 stocks worth ₹1,495 cr at Oct 2026 end. Largest: Sun Pharmaceutical Industries 7.9 %, Abbott India 5.7 %, Divi's Laboratories 5.4 %, Healthcare Global Enterprises 5.3 %, Dr. Reddy's Laboratories 5.2 %. Sun Pharmaceutical Industries mutual fund holdings · Abbott India mutual fund holdings · Divi's Laboratories mutual fund holdings
Which stocks did Rajat Srivastava buy and sell in Oct 2026?
In Oct 2026, Rajat Srivastava's schemes added to 13 stocks, largest Biocon (BIOCON), Sanofi Consumer Healthcare India (SANOFICONR), Natco Pharma (NATCOPHARM); cut 10, largest Fortis Healthcare (FORTIS), PI Industries (PIIND), Dr. Lal Path Labs (LALPATHLAB), by value at month-end prices.
Which mutual fund schemes does Rajat Srivastava manage?
AMFI's scheme summary documents name Rajat Srivastava (Tata Mutual Fund) for 1 scheme: Tata India Pharma & Healthcare Fund. Tata India Pharma & Healthcare Fund portfolio